News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,723 Results
Type
Article (14152)
Company Profile (285)
Press Release (251286)
Section
Business (79499)
Career Advice (153)
Deals (13223)
Drug Delivery (35)
Drug Development (50426)
Employer Resources (31)
FDA (5710)
Job Trends (5127)
News (144365)
Policy (10029)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (6)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (909)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21623)
ALS (57)
Alzheimer's disease (813)
Antibody-drug conjugate (ADC) (79)
Approvals (5717)
Artificial intelligence (102)
Autoimmune disease (8)
Automation (5)
Bankruptcy (104)
Best Places to Work (4560)
BIOSECURE Act (5)
Biosimilars (38)
Biotechnology (233)
Bladder cancer (40)
Brain cancer (19)
Breast cancer (135)
Cancer (1190)
Cardiovascular disease (95)
Career advice (132)
Career pathing (2)
CAR-T (102)
Cell therapy (295)
Cervical cancer (5)
Clinical research (40740)
Collaboration (477)
Compensation (206)
Complete response letters (13)
COVID-19 (1031)
CRISPR (35)
C-suite (131)
Cystic fibrosis (75)
Data (1242)
Denatured (11)
Depression (28)
Diabetes (115)
Diagnostics (1285)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (75)
Drug pricing (27)
Drug shortages (3)
Duchenne muscular dystrophy (66)
Earnings (29462)
Editorial (16)
Employer branding (4)
Employer resources (29)
Events (47941)
Executive appointments (384)
FDA (6275)
Featured Employer (32)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (440)
Gene editing (84)
Generative AI (9)
Gene therapy (219)
GLP-1 (345)
Government (1074)
Grass and pollen (2)
Guidances (18)
Healthcare (6586)
Huntington's disease (21)
IgA nephropathy (19)
Immunology and inflammation (73)
Indications (17)
Infectious disease (1087)
Inflammatory bowel disease (109)
Inflation Reduction Act (8)
Influenza (16)
Intellectual property (52)
Interviews (17)
IPO (7259)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (6)
Labor market (4)
Layoffs (198)
Leadership (2)
Legal (1385)
Liver cancer (30)
Lung cancer (169)
Lymphoma (79)
Machine learning (1)
Management (7)
Manufacturing (111)
MASH (46)
Medical device (2587)
Medtech (2588)
Mergers & acquisitions (6230)
Metabolic disorders (346)
Multiple sclerosis (48)
NASH (13)
Neurodegenerative disease (53)
Neuropsychiatric disorders (22)
Neuroscience (1162)
NextGen: Class of 2025 (2016)
Non-profit (852)
Northern California (1449)
Now hiring (21)
Obesity (181)
Opinion (99)
Ovarian cancer (50)
Pain (39)
Pancreatic cancer (49)
Parkinson's disease (99)
Partnered (6)
Patents (101)
Patient recruitment (60)
Peanut (35)
People (25440)
Pharmaceutical (49)
Pharmacy benefit managers (5)
Phase I (14381)
Phase II (18952)
Phase III (11982)
Pipeline (604)
Podcasts (43)
Policy (34)
Postmarket research (852)
Preclinical (6024)
Press Release (30)
Prostate cancer (50)
Psychedelics (35)
Radiopharmaceuticals (210)
Rare diseases (265)
Real estate (1427)
Recruiting (12)
Regulatory (8511)
Reports (14)
Research institute (936)
Resumes & cover letters (17)
Rett syndrome (3)
RNA editing (2)
RSV (10)
Schizophrenia (54)
Series A (85)
Series B (53)
Service/supplier (2)
Sickle cell disease (37)
Southern California (1292)
Special edition (11)
Sponsored (11)
Startups (1970)
State (1)
Stomach cancer (4)
Supply chain (18)
The Weekly (32)
United States (11464)
Vaccines (198)
Venture capitalists (27)
Webinars (7)
Weight loss (101)
Women's health (14)
Worklife (2)
Date
Today (34)
Last 7 days (340)
Last 30 days (1711)
Last 365 days (20114)
2025 (3850)
2024 (20557)
2023 (22417)
2022 (26824)
2021 (27806)
2020 (23359)
2019 (16224)
2018 (11739)
2017 (13748)
2016 (11843)
2015 (14351)
2014 (10392)
2013 (7486)
2012 (7538)
2011 (7615)
2010 (7431)
Location
Africa (148)
Alabama (37)
Alaska (2)
Arizona (50)
Arkansas (5)
Asia (17161)
Australia (2905)
California (3321)
Canada (1019)
China (294)
Colorado (127)
Connecticut (141)
Delaware (84)
Europe (36912)
Florida (386)
Georgia (99)
Idaho (16)
Illinois (202)
India (7)
Indiana (83)
Iowa (1)
Japan (65)
Kansas (58)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (428)
Massachusetts (2619)
Michigan (70)
Minnesota (129)
Mississippi (1)
Missouri (22)
Montana (14)
Nebraska (4)
Nevada (14)
New Hampshire (13)
New Jersey (834)
New Mexico (12)
New York (911)
North Carolina (502)
North Dakota (4)
Northern California (1449)
Ohio (102)
Oklahoma (8)
Oregon (21)
Pennsylvania (631)
Puerto Rico (2)
Rhode Island (13)
South America (207)
South Carolina (3)
Southern California (1292)
Tennessee (24)
Texas (372)
Utah (47)
Virginia (66)
Washington D.C. (27)
Washington State (308)
Wisconsin (13)
265,723 Results for "sorrento therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
Virpax ® Pharmaceuticals, Inc. today announced that it has entered into a term sheet to settle the litigation with the Company and Sorrento Therapeutics, Inc. (Sorrento) and Scilex Pharmaceuticals, Inc. (Scilex and Sorento, collectively, the “Plaintiffs”).
February 27, 2024
·
5 min read
Biotech Beach
Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company
Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento” or “Company”) announced the consummation on September 21, 2023, of the previously announced sale to Scilex Holding Company (Nasdaq: SCLX, “Scilex”) of certain securities that Sorrento held in Scilex.
September 22, 2023
·
5 min read
Press Releases
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025
January 31, 2025
·
7 min read
Drug Development
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) announced today positive Phase 2a top-line clinical trial results for the RTX program.
September 7, 2023
·
13 min read
Deals
Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.
Scilex Holding Company announced the consummation of the previously announced purchase of securities from Sorrento Therapeutics, Inc..
September 21, 2023
·
8 min read
Deals
Sorrento Therapeutics, Inc.'s Bankruptcy Court Extends the Lockup Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividend
Sorrento Therapeutics, Inc. announced that, in connection with its ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas entered an order extending the expiration of the restrictions on transfer on the shares of common stock of Scilex Holding Company that were distributed by Sorrento to its stockholders as a dividend on January 19, 2023.
April 25, 2023
·
6 min read
Deals
Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. and an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, together with Sorrento, issued the following statements:.
February 13, 2023
·
10 min read
Deals
Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announced that on September 11, 2023, Scilex, Oramed Pharmaceuticals Inc. and Sorrento executed non-binding term sheets relating to, among other things, the Securities Transfer and the Note.
September 13, 2023
·
9 min read
Deals
Sorrento Therapeutics, Inc.'s Bankruptcy Court Approves Elective Offering of Restricted Common Stock of Scilex Holding Company for Dividend Short Holders
Sorrento Therapeutics, Inc. announced that, in connection with its ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas entered an order approving an offering of a portion of Sorrento’s common stock in its non-debtor public subsidiary, Scilex Holding Company.
July 20, 2023
·
6 min read
Biotech Beach
Sorrento Therapeutics, Inc. Receives Final Court Approval for $75 Million Debtor-In-Possession Financing
Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) today announced that the U.S. Bankruptcy Court for the Southern District of Texas granted final approval of Sorrento’s $75 million debtor-in-possession (DIP) financing from JMB Capital Partners, in connection with Sorrento’s chapter 11 case that was filed on February 13, 2023.
March 29, 2023
·
6 min read
1 of 26,573
Next